–Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development–
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) — Capricor Therapeutics, Inc., (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced new data describing a scalable framework for loading therapeutic small interfering RNAs (siRNA) and phosphorodiamidate morpholino oligomers (PMO) into exosomes. The data were presented at the 2025 American Association for Extracellular Vesicles (AAEV) Annual Meeting in Salt Lake City, Utah, held from November 20-23, 2025.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
